Metformin and colorectal cancer risk in diabetic patients.

Diabetes Care · 2011 · PMC3177744 · PMID 21949227

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The results of these two randomized controlled trials suggest little difference between metformin and rosiglitazone in malignancy risk, whereas sulfonylureas appeared to be associated with an increased risk that did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.